Anti-carcinogenic properties of omeprazole against human colon cancer cells and azoxymethane-induced colonic aberrant crypt foci formation in rats

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 170-175

  Patlolla, Jagan M R ^a   Zhang, Yuting ^a   Li, Qian ^a   Steele, Vernon E ^b   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Aberrant crypt foci; Apoptosis; Chemoprevention; Colon cancer; Omeprazole

Indexed keywords

AZOXYMETHANE; OMEPRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PREVENTION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; INTESTINE CRYPT; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; AZOXYMETHANE; CELL GROWTH PROCESSES; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HCT116 CELLS; HUMANS; MALE; OMEPRAZOLE; PRECANCEROUS CONDITIONS; RANDOM ALLOCATION; RATS; RATS, INBRED F344;

EID: 84455171380     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1214     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Der G: An overview of proton pump inhibitors. Gastroenterol Nurs 26: 182-190, 2003.
3. Martin de Argila C: Safety of potent gastric acid inhibition. Drugs 65: 97-104, 2005.
4. De Milito A, Iessi E, Logozzi M, et al: Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspaseindependent mechanism involving reactive oxygen species. Cancer Res 67: 5408-5417, 2007. (Pubitemid 46997281)
5. Marino ML, Fais S, Djavaheri-Mergny M, et al: Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis 1: e87, 2010.
6. Yeo M, Kim DK, Kim YB, et al: Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 10: 8687-8696, 2004. (Pubitemid 40053438)
7. Tobi M, Chintalapani S, Goo R, et al: Omeprazole inhibits growth of cancer cell line of colonic origin. Dig Dis Sci 40: 1526-1530, 1995.
8. Tagaki T, Naito Y, Okada H, et al: Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxidase-1 via activation of NF-E2-related factor 2 and oxidation of Kelch-like ECH-associated protein 1. J Pharmacol Exp Ther 331: 255-264, 2009.
9. Becker JC, Grosser N, Waltke C, et al: Beyond gastric acid reduction: proton pump inhibitors induce heme oxigenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 345: 1014-1021, 2006. (Pubitemid 43776514)
10. Penman ID, el-Omar E, McGregor JR, Hillan KJ, O'Dwyer PJ and McColl KE: Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats. Gut 34: 1559-1565, 1993. (Pubitemid 23341848)
11. Kim YJ, Lee JS, Hong KS, Chung JW, Kim JH and Hahm KB: Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression. Cancer Prev Res (Phila) 3: 963-974, 2010.
12. Hurwitz A, Sztern MI, Looney GA, Pinson DM, Bauer KD and Kimler BF: Effects of omeprazole on cell kinetics of carcinogeninduced colon tumors in rats. Cell Prolif 28: 525-531, 1995.
13. Pinson DM, Havu N, Sztern MI, Mattsson H, Looney GA, Kimler BF and Hurwitz A: Drug-induced hypergastrinemia: absence of trophic effects on colonic carcinoma in rats. Gastroenterology 108: 1068-1074, 1995.
14. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998 (Pubitemid 28406819)
15. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999. (Pubitemid 29407357)
16. Deveraux QL and Reed JC: IAP family proteins: suppressors of apoptosis. Genes Dev 13: 239-252, 1999. (Pubitemid 29095796)
17. Salvesen GS and Duckett CS: IAP proteins: blocking the road to death's door. Nat Mol Cell Biol 3: 401-410, 2002. (Pubitemid 34685698)
18. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Olsterdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998. (Pubitemid 28551107)
19. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54, 2003.
20. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin expressed in cancer and Lymphoma. Nat Med 3: 917-921, 1997. (Pubitemid 27353455)
21. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074, 1998. (Pubitemid 28521163)
22. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R and Shroyer KR: Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 32: 119-125, 2001. (Pubitemid 32150638)
23. Kim PJ, Plescia J, Clevers H, Fearon ER and Altieri DC: Survivin and molecular pathogenesis of colorectal cancer. Lancet 362: 205-209, 2003.
24. American Institute of Nutrition: Report of the American Institute of Nutrition ad hoc committee on standards for nutritional studies. J Nutr 107: 1340-1348, 1977.
25. Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37: 147-151, 1987.
26. Patlolla JM, Raju J, Swamy MV and Rao CV: Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21waf1/cip1 in colon cancer cells. Mol Cancer Ther 5: 1459-1466, 2006. (Pubitemid 44070482)
27. Rosenberg DW, Giardina C and Tanaka T: Mouse models for the study of colon carcinogenesis. Carcinogenesis 30: 183-196, 2009.
28. Mutoh M, Lung FD, Long YQ, Roller RP, Sikorski RS and O'Connor PMA: p21(Waf1/Cip1) carboxy-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res 59: 3480-3488, 1999. (Pubitemid 29334512)
29. Cai K and Dynlacht BD: Activity and nature of p21WAF1/CIP1 complexes during the cell cycle. Proc Natl Acad Sci USA 95: 12254-12259, 1998.
30. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
31. Pastorino JG, Chen ST, Tafani M, Snyder JW and Farber JL: The over expression of Baxproduces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 273: 7770-7775, 1998.
32. Scaringi L, Cornacchione P, Ayroldi E, Corazzi L, Capodicasa E, Rossi R and Marconi P: Omeprazole induces apoptosis in jurkat cells. Int J Immunopathol Pharmacol 17: 331-342, 2004.
33. Marsden VS, O'Connor L, O'Reilly LA, et al: Apoptosis initiated by Bcl-2 regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 419: 634-637, 2002.
34. Zhang T, Otevrel T, Gao Z, et al: Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664-8667, 2001.
35. Li H, Pamukcu R and Thompson WJ: beta-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther 1: 621-625, 2002.